-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The R&D team of Nanjing Chenruisheng has recently conquered the research and development of somaglutide CAS: 910463-68-2 and alfanotide API, and has become one of the few comprehensive enterprises in China that integrates synthetic R&D, customized development and integration
.
CAS No.
: 910463-68-2 Molecular formula: C187H291N45O59 Molecular weight: 4113.
57754EINECS No.
: 203-405-2 Semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which is more effective in treating type 2 diabetes
.
The liraglutide compound has expired, and generic drugmakers are eyeing it
.
In order to prevent problems before they happen, Novo Nordisk has already prepared the next generation of liraglutide, which is semaglutide
.
Structurally, Semeglutide is a GLP-1(7-37) chain where Aib at position 8 is substituted for Ala, Arg at position 34 is substituted for Lys, and Lys at position 26 is connected to an octadecanoic acid aliphatic chain
.
Compared with Liraglutide, Semeglutide has a longer aliphatic chain and increased hydrophobicity, but Semeglutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced
.
After PEG modification, it can not only bind closely to albumin, cover the enzymatic hydrolysis site of DPP-4, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation
.
.
CAS No.
: 910463-68-2 Molecular formula: C187H291N45O59 Molecular weight: 4113.
57754EINECS No.
: 203-405-2 Semaglutide is a long-acting dosage form developed based on the basic structure of liraglutide, which is more effective in treating type 2 diabetes
.
The liraglutide compound has expired, and generic drugmakers are eyeing it
.
In order to prevent problems before they happen, Novo Nordisk has already prepared the next generation of liraglutide, which is semaglutide
.
Structurally, Semeglutide is a GLP-1(7-37) chain where Aib at position 8 is substituted for Ala, Arg at position 34 is substituted for Lys, and Lys at position 26 is connected to an octadecanoic acid aliphatic chain
.
Compared with Liraglutide, Semeglutide has a longer aliphatic chain and increased hydrophobicity, but Semeglutide is modified with a short chain of PEG, and its hydrophilicity is greatly enhanced
.
After PEG modification, it can not only bind closely to albumin, cover the enzymatic hydrolysis site of DPP-4, but also reduce renal excretion, prolong the biological half-life, and achieve the effect of long circulation
.
